Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Short-term budget affordability of hepatitis C treatments for state Medicaid programs

Fig. 2

Total infected population per treatment scenario, by state over 10 years. a Total infected population, North Carolina. Notes: Baseline treats 6% of patients with Metavir fibrosis score F2 and above, excluding PWIDs. Remove Sobriety Restrictions treats 6% of patients with F2 and above, including PWIDs. Treat Early assumes a 66% diagnosis rate, treating 8% of patients with fibrosis score F0 and above, excluding PWIDs. Remove Access Restrictions treats 8% of patients with F0 and above, including PWIDs. b Total infected population, Oregon. Notes: Baseline treats 10% of patients with Metavir fibrosis score F3 and above, excluding PWIDs. Remove Sobriety Restrictions treats 10% of patients with F3 and above, including PWIDs. Treat Early assumes a 66% diagnosis rate, treating 13% of patients with fibrosis score F0 and above, excluding PWIDs. Remove Access Restrictions treats 13% of patients with F0 and above, including PWIDs. c Total infected population, Wisconsin. Notes: Baseline treats 18% of patients with Metavir fibrosis score F3 and above, excluding PWIDs. Remove Sobriety Restrictions treats 18% of patients with F3 and above, including PWIDs. Treat Early assumes 66% a diagnosis rate, treating 24% of patients with fibrosis score F0 and above, excluding PWIDs. Remove Access Restrictions treats 24% of patients with F0 and above, including PWIDs

Back to article page